2022
Post‐treatment effects of topiramate on alcohol‐related outcomes: A combined analysis of two placebo‐controlled trials
Kranzler HR, Feinn R, Pond T, Hartwell E, Gelernter J, Crist RC, Witkiewitz K. Post‐treatment effects of topiramate on alcohol‐related outcomes: A combined analysis of two placebo‐controlled trials. Addiction Biology 2022, 27: e13130. PMID: 35229945, PMCID: PMC9257958, DOI: 10.1111/adb.13130.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DrinkingAlcoholismDouble-Blind MethodFemaleFructoseHumansMaleMiddle AgedReceptors, Kainic AcidTopiramateConceptsAlcohol use disorderPost-treatment periodAlcohol-related outcomesAlcohol-related problemsTopiramate's effectsSingle nucleotide polymorphismsPlacebo-controlled trialPrimary treatment outcomeOptimal treatment durationSelf-reported alcohol consumptionTrial of topiramatePost-treatment effectsTopiramate groupPlacebo groupSecond RCTMedication effectsTreatment outcomesProblematic alcohol useTopiramateTreatment durationUse disordersAlcohol consumptionΓ-glutamyltransferaseRobust effectGenotype groups
2019
Genomewide Gene-by-Sex Interaction Scans Identify ADGRV1 for Sex Differences in Opioid Dependent African Americans
Yang BZ, Zhou H, Cheng Z, Kranzler HR, Gelernter J. Genomewide Gene-by-Sex Interaction Scans Identify ADGRV1 for Sex Differences in Opioid Dependent African Americans. Scientific Reports 2019, 9: 18070. PMID: 31792237, PMCID: PMC6889277, DOI: 10.1038/s41598-019-53560-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAllelesAnalgesics, OpioidBlack or African AmericanBrainCalcium-Binding ProteinsFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMaleMiddle AgedOpioid-Related DisordersPolymorphism, Single NucleotideReceptors, G-Protein-CoupledReceptors, Kainic AcidSex FactorsWhite PeopleConceptsOpioid dependenceOD riskSex-different effectsSex differencesInferior olivary nucleusDSM-IV diagnosisDimorphic riskSubstantia nigraAA menOlivary nucleusFrontal cortexEuropean-American subjectsADGRV1Further studiesRiskAfrican AmericansGenetic variantsDisease enrichment analysisBrainSex interactionNominal significanceMenFirst studyPutamenLung
2017
GRIK1 and GABRA2 Variants Have Distinct Effects on the Dose‐Related Subjective Response to Intravenous Alcohol in Healthy Social Drinkers
Yang B, Arias AJ, Feinn R, Krystal JH, Gelernter J, Petrakis IL. GRIK1 and GABRA2 Variants Have Distinct Effects on the Dose‐Related Subjective Response to Intravenous Alcohol in Healthy Social Drinkers. Alcohol Clinical And Experimental Research 2017, 41: 2025-2032. PMID: 29131352, PMCID: PMC5764175, DOI: 10.1111/acer.13516.Peer-Reviewed Original Research
2014
Posttreatment Effects of Topiramate Treatment for Heavy Drinking
Kranzler HR, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J. Posttreatment Effects of Topiramate Treatment for Heavy Drinking. Alcohol Clinical And Experimental Research 2014, 38: 3017-3023. PMID: 25581656, PMCID: PMC4293099, DOI: 10.1111/acer.12578.Peer-Reviewed Original ResearchConceptsPercent days abstinentHeavy drinking daysTopiramate treatmentHeavy drinkingDrinking daysHeavy drinkersAllele homozygotesPlacebo-controlled trialEffects of topiramateEnd of treatmentPersistent therapeutic effectKainate receptor subunitsHigher percent days abstinentTherapeutic effectTreatment goalsAlcohol-related problemsAllele carriersDays abstinentAbstinent daysPosttreatment effectsReceptor subunitsReduced drinkingSingle nucleotide polymorphismsStatistical significanceComplete dataTopiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism
Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM. Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism. American Journal Of Psychiatry 2014, 171: 445-452. PMID: 24525690, PMCID: PMC3997125, DOI: 10.1176/appi.ajp.2013.13081014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismDouble-Blind MethodFemaleFructoseHumansMaleMiddle AgedPolymorphism, Single NucleotideReceptors, Kainic AcidTopiramateTreatment OutcomeConceptsHeavy drinking daysHeavy drinkersTopiramate treatmentDaily doseHeavy drinkingTopiramate's effectsDrinking daysAbstinent daysUse of topiramateMaximal daily doseWeeks of treatmentC allele homozygotesPersonalized treatment optionsEnzyme γ-glutamyl transpeptidasePlacebo groupΓ-glutamyl transpeptidaseTreatment optionsTreatment completionPharmacogenetic findingsTreatment goalsAlcohol-related problemsKainate receptorsTreatment groupsBrief counselingAlcohol dependence
2009
Association of Markers in the 3′ Region of the GluR5 Kainate Receptor Subunit Gene to Alcohol Dependence
Kranzler HR, Gelernter J, Anton RF, Arias AJ, Herman A, Zhao H, Burian L, Covault J. Association of Markers in the 3′ Region of the GluR5 Kainate Receptor Subunit Gene to Alcohol Dependence. Alcohol Clinical And Experimental Research 2009, 33: 925-930. PMID: 19320626, PMCID: PMC2772659, DOI: 10.1111/j.1530-0277.2009.00913.x.Peer-Reviewed Original Research